Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Robert H. Lurie Comprehensive Cancer Center of Northwestern University · Royal Marsden Hospital · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,815
total citations
- FWCI
- 150.63
- Percentile
- 100%
- References
- 32
Citations per year
Authors
18- MCMassimo CristofanilliCorresponding
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- NCNicholas C. Turner
Royal Marsden Hospital, Institute of Cancer Research
- IBIgor Bondarenko
Dnipro State Medical University
- JRJungsil Ro
National Cancer Center
- SISeock‐Ah Im
Seoul National University Hospital
Topics & keywords
Topics
Keywords
- Fulvestrant
- Palbociclib
- Metastatic breast cancer
- Medicine
- Placebo
- Internal medicine
- Oncology
- Gynecology
No related works found for this paper.